Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 9,580,000 shares, a growth of 16.8% from the November 15th total of 8,200,000 shares. Based on an average daily volume of 1,190,000 shares, the short-interest ratio is currently 8.1 days.
Adaptive Biotechnologies Price Performance
ADPT stock traded up $0.14 during trading on Friday, hitting $6.30. 1,183,285 shares of the company traded hands, compared to its average volume of 1,411,340. The stock's 50-day simple moving average is $5.37 and its 200 day simple moving average is $4.57. Adaptive Biotechnologies has a 1 year low of $2.28 and a 1 year high of $7.07. The company has a market cap of $929.75 million, a PE ratio of -4.70 and a beta of 1.49.
Institutional Investors Weigh In On Adaptive Biotechnologies
A number of institutional investors have recently modified their holdings of the business. JTC Employer Solutions Trustee Ltd purchased a new position in Adaptive Biotechnologies during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Adaptive Biotechnologies during the 3rd quarter valued at approximately $34,000. Rothschild Investment LLC acquired a new stake in Adaptive Biotechnologies in the 2nd quarter valued at $36,000. MQS Management LLC purchased a new stake in Adaptive Biotechnologies in the 2nd quarter worth $36,000. Finally, Nisa Investment Advisors LLC raised its position in Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company's stock worth $48,000 after acquiring an additional 11,852 shares during the period. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ADPT has been the subject of a number of analyst reports. Piper Sandler upped their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. BTIG Research raised their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd.
Get Our Latest Stock Report on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Further Reading
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
